Clinical Research Directory
Browse clinical research sites, groups, and studies.
NAC for Treatment-Resistant OCD and Other Related Disorders
Sponsor: Guangdong Provincial People's Hospital
Summary
This is a randomized, double-blind, placebo-controlled study investigating N-acetylcysteine (NAC) as an augmentation therapy for individuals with treatment-resistant obsessive-compulsive disorder (TR-OCD), studied within a broader cohort of treatment-resistant Obsessive-Compulsive and Related Disorders (OCRDs). The study's primary aim is to investigate the neurobiological mechanism by which NAC improves inhibitory control deficits in TR-OCD. This is achieved by using Magnetic Resonance Spectroscopy (MRS) to measure changes in thalamic glutamatergic metabolism. A secondary aim is to assess the clinical efficacy of this augmentation strategy on symptom severity. The central hypothesis is that improvements in inhibitory control are mediated by NAC-induced changes in brain glutamate levels.
Official title: Altered Brain Glutamate Level and Inhibitory Control in Treatment-Resistant Obsessive-Compulsive Disorder After N-acetylcysteine (NAC) Augmentation Therapy
Key Details
Gender
All
Age Range
12 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2022-06-22
Completion Date
2025-11-13
Last Updated
2025-09-03
Healthy Volunteers
Yes
Conditions
Interventions
N-Acetylcysteine Tablets
In addition to participants' existing medication regimens, NAC will be added.
Placebo Oral Tablet
Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.
Locations (1)
Guangdong Mental Health Center, Guangdong Provincial People's Hospital
GuangDong, Guangdong, China